Tearsheet

Sarepta Therapeutics (SRPT)

Market Price (11/5/2025): $16.53 | Market Cap: $1.6 Bil
Sector: Health Care | Industry: Biotechnology

Sarepta Therapeutics (SRPT)

Market Price (11/5/2025): $16.53
Market Cap: $1.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 65%	Weak multi-year price returns 2Y Excs Rtn is -137%, 3Y Excs Rtn is -160%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -0.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 0.0%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -93%		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -18%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.1%
3			High stock price volatility Vol 12M is 103%

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 65%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -93%
2	Weak multi-year price returns 2Y Excs Rtn is -137%, 3Y Excs Rtn is -160%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -0.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 0.0%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -18%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.1%
6	High stock price volatility Vol 12M is 103%

Market Valuation & Key Metrics

	11/5/25	2024	2023	2022	2021
Share Price CYE	$16.53	$121.59	$96.43	$129.58	$90.05
Market Cap CYE ($ Bil)	1.6	17.9	10.0	11.4	7.7
Total Debt ($ Bil)	1.4	1.3	1.4	1.6	1.2
Total Cash ($ Bil)	0.8	1.4	1.7	2.0	2.1
Enterprise Value ($ Bil)	2.2	19.2	11.4	13.0	8.9
Valuation Ratios
P/S TTM	0.7	6.9	7.2	12.2	10.4
P/EBIT TTM	-323.6	47.0	-17.9	-17.8	-20.6
P/E TTM	-27.9	55.8	-16.6	-16.1	-17.5
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0	4.6	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.3	-1.3	-2.7
P/E TTM (Sector)	-1.9	-1.5	-1.5	-1.3	-2.8

	11/5/25	2024	2023
Share Price CYE	$16.53	$121.59	$96.43
Market Cap CYE ($ Bil)	1.6	17.9	10.0
Total Debt ($ Bil)	1.4	1.3	1.4
Total Cash ($ Bil)	0.8	1.4	1.7
Enterprise Value ($ Bil)	2.2	19.2	11.4
Valuation Ratios
P/S TTM	0.7	6.9	7.2
P/EBIT TTM	-323.6	47.0	-17.9
P/E TTM	-27.9	55.8	-16.6
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.3
P/E TTM (Sector)	-1.9	-1.5	-1.5

	SRPT	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	2.5
Rev Chg Q	68.4%	6.7%
Rev Chg LTM	64.9%	5.6%
Rev Chg 3Y Avg	45.0%	5.3%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.3
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-0.0%	18.8%
CFO/Rev LTM	-12.1%	20.4%
Net Inc Mgn	-2.3%	12.9%
VALUATION	VERY LOW
P/S	0.7	3.1
P/CFO	-5.4	15.2
P/FCF	-3.6	20.3
P/E	-28.0	23.7
STABILITY	GOOD
Debt/Equity	0.84	0.21
Cash/Assets	0.22	0.07

AI Generated Analysis | Feedback

null

SRPT Stock

Return (1M):

Factor Drivers of Stock Movement

The -3.3% change in SRPT stock from 8/5/2025 to 11/4/2025 was primarily driven by a -12.4% change in the company's P/S Multiple.

	8052025	11042025	Change
Stock Price ($)	16.75	16.20	-3.28%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	2233.37	2481.53	11.11%
P/S Multiple	0.73	0.64	-12.38%
Shares Outstanding (Mil)	97.36	98.00	-0.66%
Cumulative Contribution			-3.29%

LTM = Last Twelve Months as of date shown

The -65.3% change in SRPT stock from 5/6/2025 to 11/4/2025 was primarily driven by a -68.6% change in the company's P/S Multiple.

	5062025	11042025	Change
Stock Price ($)	46.75	16.20	-65.35%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	2233.37	2481.53	11.11%
P/S Multiple	2.04	0.64	-68.61%
Shares Outstanding (Mil)	97.36	98.00	-0.66%
Cumulative Contribution			-65.35%

LTM = Last Twelve Months as of date shown

The -86.8% change in SRPT stock from 11/4/2024 to 11/4/2025 was primarily driven by a -91.7% change in the company's P/S Multiple.

	11042024	11042025	Change
Stock Price ($)	123.07	16.20	-86.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1504.99	2481.53	64.89%
P/S Multiple	7.74	0.64	-91.73%
Shares Outstanding (Mil)	94.62	98.00	-3.58%
Cumulative Contribution			-86.85%

LTM = Last Twelve Months as of date shown

The -84.4% change in SRPT stock from 11/5/2022 to 11/4/2025 was primarily driven by a -93.8% change in the company's P/S Multiple.

	11052022	11042025	Change
Stock Price ($)	103.63	16.20	-84.37%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	876.05	2481.53	183.26%
P/S Multiple	10.37	0.64	-93.83%
Shares Outstanding (Mil)	87.63	98.00	-11.84%
Cumulative Contribution			-84.59%

LTM = Last Twelve Months as of date shown

Why The Stock Moved

AI Generated Analysis | Feedback

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SRPT Return	32%	-47%	44%	-26%	26%	-87%	-81%
Peers Return	75%	15%	-13%	-22%	-18%	39%	55%
S&P 500 Return	16%	27%	-19%	24%	23%	15%	112%
Monthly Win Rates [3]
SRPT Win Rate	42%	50%	83%	50%	58%	30%
Peers Win Rate	50%	47%	52%	38%	32%	60%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
SRPT Max Drawdown	-36%	-61%	-30%	-48%	-3%	-90%
Peers Max Drawdown	-44%	-24%	-43%	-46%	-48%	-39%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ALNY, IONS, MRNA, ARWR, APM. See SRPT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 11/4/2025 (YTD)

How Low Can It Go

Unique Key	Event	SRPT	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-63.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	172.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-37.4%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	59.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	54 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-54.9%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	121.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	265 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-85.0%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	566.7%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1385 days	1480 days

Compare to ALNY, IONS, MRNA, ARWR, APM

In The Past

Sarepta Therapeutics's stock fell -63.2% during the 2022 Inflation Shock from a high on 1/1/2021. A -63.2% loss requires a 172.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

AI Generated Analysis | Feedback

The Eli Lilly of Duchenne muscular dystrophy.
Vertex Pharmaceuticals, but for rare muscle diseases like Duchenne muscular dystrophy.
Moderna, but focused on developing genetic therapies for rare muscle disorders instead of vaccines.

AI Generated Analysis | Feedback

Exondys 51 (eteplirsen): An antisense oligonucleotide approved to treat Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping.
Vyondys 53 (golodirsen): An antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.
Amondys 45 (casimersen): An antisense oligonucleotide used to treat Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping.
Elevidys (delandistrogene moxeparvovec): A gene therapy approved for the treatment of ambulatory pediatric patients with Duchenne muscular dystrophy who have a confirmed mutation in the *DMD* gene.

AI Generated Analysis | Feedback

Sarepta Therapeutics (SRPT) primarily sells its pharmaceutical products to other companies, specifically major specialty distributors and pharmacies, rather than directly to individual patients. These distributors then supply the products to hospitals, infusion centers, and specialty pharmacies, which ultimately dispense them to patients.

Based on their latest financial filings (2023 10-K), Sarepta's major customers that accounted for more than 10% of total revenues in recent years include:

McKesson Corporation (Symbol: MCK)
Cencora, Inc. (Symbol: COR, formerly AmerisourceBergen Corporation)
Cardinal Health, Inc. (Symbol: CAH, accounted for >10% of revenues in 2021)

AI Generated Analysis | Feedback

Lonza Group AG (LONN.SW)
Catalent, Inc. (CTLT)

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

The primary clear emerging threat to Sarepta Therapeutics (SRPT) is the ongoing development and potential future market entry of competing gene therapies for Duchenne Muscular Dystrophy (DMD) from large pharmaceutical companies.

Specifically, Pfizer's gene therapy, fordadistrogene movaparvovec, is a direct competitor to Sarepta's Elevidys (delandistrogene moxeparvovec). While Pfizer recently reported that its Phase 3 CIFFREO study did not meet its primary endpoint, the company continues to pursue the development of this therapy and has significant resources for potential future iterations, alternative strategies, or commercialization. The presence of a major pharmaceutical player developing a therapy for the same rare disease, using a similar mechanism, represents a direct competitive threat to Sarepta's flagship gene therapy and its market position.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

Better Bets than Sarepta Therapeutics (SRPT)

	SRPT	Better Performance than SRPT
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	64.9%	MDGL (3422.0%), CYTK (2635.7%), AXSM (69.8%), KRYS (116.1%), PTCT (96.0%)
Rev Chg 3Y Avg	45.0%	ALNY (51.4%), BBIO (727.6%), CYTK (824.6%), RYTM (137.5%), AXSM (699.5%)
Op Mgn LTM	-0.0%	ABBV (23.5%), AMGN (23.5%), GILD (37.4%), REGN (26.7%), ALNY (8.2%)
CFO/Rev LTM	-12.1%	ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM	-18.3%	ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield	-3.7%	ABBV (4.0%), AMGN (7.3%), GILD (6.7%), VRTX (3.4%), REGN (7.5%)

	SRPT	Better Performance than SRPT
Metric	Value	Sector (Health Care)
Rev Chg LTM	64.9%	MDGL (3422.0%), HIMS (78.0%), CYTK (2635.7%), AXSM (69.8%), KRYS (116.1%)
Rev Chg 3Y Avg	45.0%	ALNY (51.4%), BBIO (727.6%), HIMS (71.0%), CYTK (824.6%), RYTM (137.5%)
Op Mgn LTM	-0.0%	LLY (43.0%), JNJ (26.2%), ABBV (23.5%), UNH (6.1%), ABT (17.6%)
CFO/Rev LTM	-12.1%	LLY (20.5%), JNJ (26.3%), ABBV (33.1%), UNH (4.8%), ABT (20.8%)
FCF/Rev LTM	-18.3%	LLY (-0.1%), JNJ (20.3%), ABBV (31.3%), UNH (4.0%), ABT (15.8%)
Total Yield	-3.7%	LLY (2.3%), JNJ (8.3%), ABBV (4.0%), UNH (8.5%), ABT (8.2%)

	SRPT	Better Performance than SRPT
Metric	Value	All Other Sectors
Rev Chg LTM	64.9%	NVDA (71.6%), RDDT (69.7%), ALAB (163.8%), STLA (156.0%), CRDO (175.8%)
Rev Chg 3Y Avg	45.0%	NVDA (92.0%), APO (129.8%), NU (70.1%), LVS (51.6%), RDDT (45.3%)
Op Mgn LTM	-0.0%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM	-12.1%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM	-18.3%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-3.7%	NVDA (1.8%), AAPL (2.8%), MSFT (3.4%), GOOGL (4.0%), AMZN (2.7%)

		Best Bets In Health Care Sector
	SRPT	RPRX	HALO	CPRX	BMY	LNTH	MEDP	PBH	MRK	NBIX	ISRG
What You Pay
P/E	-27.4	15.7	13.4	12.5	15.4	14.6	38.6	14.1	12.8	33.3	69.9
P/EBIT	-317.1	8.3	10.4	10.7	9.3	10.0	33.0	9.0	10.3	24.4	68.2
What You Get
Rev Chg Q	68.4%	7.7%	22.1%	19.4%	2.8%	-4.1%	23.7%	-6.6%	-1.9%	27.8%	22.9%
Rev Chg LTM	64.9%	3.0%	31.2%	28.5%	1.3%	5.7%	13.9%	0.6%	1.8%	19.6%	22.2%
Rev Chg 3Y Avg	45.0%	0.8%	29.0%	49.9%	1.0%	34.3%	19.9%	0.8%	3.7%	24.6%	16.3%
FCF/Rev 3Y Avg	-35.5%	113.4%	45.0%	38.9%	29.0%	26.1%	25.3%	21.6%	20.9%	21.1%	16.5%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Sarepta Therapeutics Stock Fell 34% in a Day, What Now?	Return
2	SRPT Stock in Focus: Does It Outshine the Peer Group?
3	SRPT Dip Buy Analysis
4	Sarepta Therapeutics Total Shareholder Return (TSR): 26.1% in 2024 and 10.5% 3-yr compounded annual returns (above peer average)
5	Sarepta Therapeutics (SRPT) Operating Cash Flow Comparison	Financials
6	Sarepta Therapeutics (SRPT) Net Income Comparison	Financials
7	Sarepta Therapeutics (SRPT) Operating Income Comparison	Financials
8	Sarepta Therapeutics (SRPT) Revenue Comparison	Financials
9	Sarepta Therapeutics vs. S&P500 Correlation	Correlation
10	Sarepta Therapeutics Price Volatility	Volatility
11	ARTICLES
12	Market Movers \| Winners: TLRY, VTLE, UP \| Losers: KDP, SRPT, FRPT		August 25th, 2025
13	SRPT Stock in Focus: Does It Outshine the Peer Group?		August 20th, 2025
14	Market Movers \| Winners: SRPT, LYEL, SMCI \| Losers: ALB, ULH, GERN		July 29th, 2025
15	Stocks Trading At 52-Week Low		July 26th, 2025
16	Stocks Trading At 52-Week Low		July 24th, 2025

	Title
0	DASHBOARDS
1	Market Movers \| Winners: TLRY, VTLE, UP \| Losers: KDP, SRPT, FRPT
2	SRPT Stock in Focus: Does It Outshine the Peer Group?
3	Market Movers \| Winners: SRPT, LYEL, SMCI \| Losers: ALB, ULH, GERN
4	Stocks Trading At 52-Week Low
5	Stocks Trading At 52-Week Low
6	ARTICLES
7	Sarepta Therapeutics Stock Fell 34% in a Day, What Now?
8	SRPT Stock in Focus: Does It Outshine the Peer Group?
9	SRPT Dip Buy Analysis
10	Sarepta Therapeutics Total Shareholder Return (TSR): 26.1% in 2024 and 10.5% 3-yr compounded annual returns (above peer average)
11	Sarepta Therapeutics (SRPT) Operating Cash Flow Comparison
12	Sarepta Therapeutics (SRPT) Net Income Comparison
13	Sarepta Therapeutics (SRPT) Operating Income Comparison
14	Sarepta Therapeutics (SRPT) Revenue Comparison
15	Sarepta Therapeutics vs. S&P500 Correlation
16	Sarepta Therapeutics Price Volatility

Trade Ideas

Select past ideas related to SRPT. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-1.8%	-1.8%	-1.8%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	3.8%	3.8%	0.0%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-8.9%	-8.9%	-8.9%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-0.7%	-0.7%	-1.2%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.0%	7.0%	-7.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-1.8%	-1.8%	-1.8%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	3.8%	3.8%	0.0%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-8.9%	-8.9%	-8.9%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-0.7%	-0.7%	-1.2%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.0%	7.0%	-7.0%

Recent Active Movers

1 Day Top Gainers

Ticker

1 Day Top Losers

Ticker

1 Week Top Gainers

Ticker

1 Week Top Losers

Ticker

1 Month Top Gainers

Ticker

1 Month Top Losers

Ticker

Recent Active Movers

1 Day Top Gainers

Ticker

1 Day Top Losers

Ticker

1 Week Top Gainers

Ticker

1 Week Top Losers

Ticker

Peer Comparisons for Sarepta Therapeutics

Financials

	SRPT	ALNY	IONS	MRNA	ARWR	APM	Median
Name	Sarepta .	Alnylam .	Ionis Ph.	Moderna	Arrowhea.	Aptorum
Mkt Price	16.20	423.47	72.88	23.75	37.85	1.41	30.80
Mkt Cap	1.6	55.7	11.6	9.2	5.3	-	9.2
Rev LTM	2,482	3,210	967	3,055	573	-	2,482
Op Inc LTM	-1	265	-278	-3,273	-108	-	-108
FCF LTM	-454	221	-309	-3,500	-18	-	-309
FCF 3Y Avg	-505	57	-420	-2,744	-298	-	-420
CFO LTM	-301	266	-247	-2,697	22	-	-247
CFO 3Y Avg	-395	108	-380	-2,055	-175	-	-380

Growth & Margins

	SRPT	ALNY	IONS	MRNA	ARWR	APM	Median
Name	Sarepta .	Alnylam .	Ionis Ph.	Moderna	Arrowhea.	Aptorum
Rev Chg LTM	64.9%	53.2%	20.4%	-38.8%	2,816.2%	-	53.2%
Rev Chg 3Y Avg	45.0%	51.4%	7.1%	-48.0%	908.8%	-	45.0%
Rev Chg Q	68.4%	149.3%	17.1%	-38.0%	-	-	42.7%
QoQ Delta Rev Chg LTM	11.1%	30.4%	2.4%	-2.7%	5.1%	-	5.1%
Op Mgn LTM	-0.0%	8.2%	-28.8%	-107.1%	-18.8%	-	-18.8%
Op Mgn 3Y Avg	-16.1%	-7.1%	-55.1%	-65.1%	-958.1%	-	-55.1%
QoQ Delta Op Mgn LTM	5.2%	15.6%	-0.5%	11.7%	2.9%	-	5.2%
CFO/Rev LTM	-12.1%	8.3%	-25.5%	-88.3%	3.8%	-	-12.1%
CFO/Rev 3Y Avg	-29.1%	3.7%	-52.4%	-51.8%	-620.8%	-	-51.8%
FCF/Rev LTM	-18.3%	6.9%	-32.0%	-114.6%	-3.1%	-	-18.3%
FCF/Rev 3Y Avg	-35.5%	1.3%	-57.4%	-67.2%	-949.2%	-	-57.4%

Valuation

	SRPT	ALNY	IONS	MRNA	ARWR	APM	Median
Name	Sarepta .	Alnylam .	Ionis Ph.	Moderna	Arrowhea.	Aptorum
Mkt Cap	1.6	55.7	11.6	9.2	5.3	-	9.2
P/S	0.6	17.3	12.0	3.0	9.2	-	9.2
P/EBIT	-317.1	427.1	-66.8	-3.1	-70.1	-	-66.8
P/E	-27.4	1,277.7	-45.4	-3.2	-35.5	-	-27.4
P/CFO	-5.3	209.4	-47.1	-3.4	240.9	-	-3.4
Total Yield	-3.7%	0.1%	-2.2%	-31.5%	-2.8%	-	-2.8%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	-	0.0%
FCF Yield 3Y Avg	-12.0%	0.0%	-6.0%	-14.3%	-8.8%	-	-8.8%
D/E	0.9	0.0	0.1	0.1	0.1	-	0.1
Net D/E	0.3	-0.0	-0.1	-0.5	-0.1	-	-0.1

Returns

	SRPT	ALNY	IONS	MRNA	ARWR	APM	Median
Name	Sarepta .	Alnylam .	Ionis Ph.	Moderna	Arrowhea.	Aptorum
1M Rtn	-28.4%	-7.2%	5.4%	-16.6%	4.8%	-37.3%	-11.9%
3M Rtn	-3.3%	1.1%	69.3%	-13.5%	129.8%	0.7%	0.9%
6M Rtn	-65.3%	57.0%	128.8%	-2.8%	189.4%	64.9%	60.9%
12M Rtn	-86.8%	56.9%	89.6%	-55.6%	88.7%	-1.4%	27.7%
3Y Rtn	-84.4%	103.3%	75.4%	-85.0%	11.5%	-78.8%	-33.7%
1M Excs Rtn	-30.8%	-6.8%	5.1%	-14.2%	0.5%	-39.7%	-10.5%
3M Excs Rtn	-7.1%	-7.8%	72.4%	-17.8%	125.3%	2.6%	-2.3%
6M Excs Rtn	-86.1%	36.2%	108.0%	-23.6%	168.6%	44.1%	40.2%
12M Excs Rtn	-105.8%	40.2%	71.2%	-75.0%	78.1%	-20.1%	10.0%
3Y Excs Rtn	-159.5%	33.5%	-10.2%	-157.9%	-68.1%	-150.9%	-109.5%

Comparison Analyses

	Title
0	Sarepta Therapeutics vs. Arrowhead Research: With Return Forecast Of 103%, Arrowhead Research Is A Better Bet
1	ALNY or SRPT - With 85% Return Forecast, SRPT Probably Deserves Your Money
2	SRPT Could Deliver 85% Returns And Outperform IONS
3	Sarepta Therapeutics vs. DexCom: With Return Forecast Of 78%, DexCom Is A Better Bet
4	Sarepta Therapeutics vs. Floor & Decor Holdings: With Return Forecast Of 72%-76%, Both Seem Like Good Bets
5	Sarepta Therapeutics vs. Capri Holdings Limited: With Return Forecast Of 72%, Sarepta Therapeutics Is A Better Bet
6	Sarepta Therapeutics vs. Royal Gold: Similar Revenue, But Sarepta Therapeutics Is A Better Bet
7	Sarepta Therapeutics vs. Coupa Software: Similar Revenue, But Coupa Software Is A Better Bet
8	Sarepta Therapeutics vs. Aspen Technology: Similar Revenue, But Sarepta Therapeutics Is A Better Bet
9	Sarepta Therapeutics vs. Under Armour: Similar Market Cap, But Sarepta Therapeutics Is A Better Bet

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/6/2025	2/28/2025	2/28/2024	2/28/2023	3/1/2022	3/1/2021	2/26/2020
Key Financials
Total Revenue	2,482	1,902	1,243	933	702	540	381
EBITDA	36	317	-454	-595	-317	-466	-659
Operating Income	-1	218	-268	-536	-450	-564	-522
Net Income	-58	235	-536	-703	-419	-554	-715
EPS	-0.59	2.34	-5.80	-8.03	-5.15	-7.11	-9.71
Growth Rates
Total Revenue Growth	64.9%	53.0%	33.3%	32.9%	30.0%	41.8%	26.5%
EBITDA Growth	-70.3%	169.8%	23.7%	-87.4%	31.9%	29.2%	-108.0%
Operating Income Growth	-102.5%	181.4%	50.1%	-19.2%	20.3%	-8.0%	-52.0%
Net Income Growth	-222.5%	143.9%	23.8%	-68.0%	24.4%	22.5%	-97.6%
Margins
EBITDA Margin	1.5%	16.7%	-36.5%	-63.8%	-45.2%	-86.3%	-173.0%
Operating Income Margin	-0.0%	11.5%	-21.5%	-57.5%	-64.1%	-104.5%	-137.2%
Net Income Margin	-2.3%	12.4%	-43.1%	-75.4%	-59.7%	-102.6%	-187.8%
Cash & Debt
Total Cash	800	1,355	1,676	1,989	2,116	1,939	1,125
Total Debt	1,354	1,343	1,397	1,617	1,153	1,073	730
Net Debt / (Cash)	554	-12	-279	-372	-962	-866	-395
Cash Flows
Net Cash from Operations	-301	-206	-501	-325	-443	107	-456
Free Cash from Operations	-454	-353	-588	-358	-484	25	-516
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/6/2025	5/6/2025	2/28/2025	11/6/2024	8/7/2024	5/1/2024	2/28/2024	11/1/2023	8/2/2023	5/2/2023	2/28/2023	11/2/2022
Key Financials Quarterly
Total Revenue	611	745	658	467	363	413	397	332	261	254	258	230
Ebitda	170	-369	187	49	27	54	57	-17	1	-495	-84	-231
Operating Income	116	-300	162	22	-1	35	25	-21	-134	-138	-107	-131
Net Income	197	-448	159	34	6	36	46	-41	-24	-517	-109	-258
EPS	2.01	-4.60	1.65	0.35	0.07	0.38	0.76	-0.46	-0.27	-5.86	-1.24	-2.94
Key Financials TTM
Total Revenue TTM	2,482	2,233	1,902	1,640	1,505	1,403	1,243	1,105	1,003	976	933	876
Ebitda TTM	36	-107	317	187	121	96	-454	-595	-809	-1,012	-595	-606
Operating Income TTM	-1	-117	218	81	38	-95	-268	-399	-510	-587	-536	-535
Net Income TTM	-58	-248	235	122	47	17	-536	-691	-908	-1,115	-703	-716
Growth Rates Quarterly
Total Revenue Growth	68.4%	80.2%	65.9%	40.8%	38.9%	63.1%	53.5%	44.1%	11.9%	20.2%	28.3%	21.6%
EBITDA Growth	525.6%	-778.9%	227.6%	386.4%	1795.7%	111.0%	167.8%	92.6%	100.7%	-537.7%	12.2%	-978.5%
Operating Income Growth	16587.4%	-960.6%	556.6%	206.5%	99.5%	125.3%	123.0%	84.1%	36.8%	-58.9%	-1.0%	-281.2%
Net Income Growth	2947.9%	-1339.0%	248.4%	182.1%	127.0%	107.0%	141.8%	84.1%	89.7%	-392.0%	10.4%	-435.3%
Margins Quarterly
EBITDA Margin	27.8%	-49.5%	28.4%	10.4%	7.5%	13.1%	14.4%	-5.1%	0.5%	-195.3%	-32.5%	-100.3%
Operating Income Margin	18.9%	-40.3%	24.6%	4.8%	-0.2%	8.4%	6.2%	-6.3%	-51.1%	-54.5%	-41.3%	-57.0%
Net Income Margin	32.2%	-60.1%	24.2%	7.2%	1.8%	8.7%	11.5%	-12.3%	-9.2%	-203.8%	-42.3%	-111.9%
Cash & Debt
Total Cash	800	523	1,355	1,198	1,460	1,391	1,676	1,734	1,861	1,882	1,989	2,072
Total Debt	1,354	1,344	1,343	1,398	1,370	1,379	1,397	1,372	1,365	1,288	1,617	1,578
Net Debt / (Cash)	554	821	-12	199	-91	-11	-279	-362	-496	-594	-372	-494
Cash Flows Quarterly
FCF from Operations	261	-583	92	-71	15	-242	-55	-115	-122	-209	-92	-65
Cash Flows TTM
FCF from Operations TTM	-301	-547	-206	-352	-396	-534	-501	-539	-489	-434	-325	-262
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	7.3%	-18.1%	10.5%	1.5%	-0.0%	2.3%	2.0%	-1.7%	-11.4%	-12.2%	-10.9%	-14.1%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-0.0%	-1.8%	3.4%	1.3%	0.5%	-0.9%	-5.3%	-8.2%	-10.9%	-12.9%	-13.7%	-14.3%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Phosphorodiamidate morpholino oligomer (PMO) Products	945	844
ELEVIDYS	200	0
Collaboration and Other	98	89	89	84
AMONDYS 45			90	0
EXONDYS 51			454	422
VYONDYS 53			69	34
Products, net					381
Total	1,243	933	702	540	381

Price Behavior

Price Behavior

Market Price	$16.20
Market Cap ($ Bil)	1.6
First Trading Date	06/04/1997
Distance from 52W High	-88.3%
	50 Days	200 Days
DMA Price	$20.32	$46.60
DMA Trend	down	up
Distance from DMA	-20.3%	-65.2%
	3M	1YR
Volatility	96.8%	102.9%
Downside Capture	486.05	282.23
Upside Capture	294.66	36.34
Correlation (SPY)	28.1%	26.3%

SRPT Betas & Captures as of 10/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.30	1.68	2.04	1.23	1.30	0.96
Up Beta	-2.35	-0.25	0.91	0.37	1.22	0.99
Down Beta	1.51	1.22	1.87	2.39	1.33	1.46
Up Capture	374%	354%	376%	-21%	22%	9%
Bmk +ve Days	14	27	37	74	145	425
Stock +ve Days	13	25	35	62	117	358
Down Capture	98%	172%	177%	267%	151%	102%
Bmk -ve Days	9	17	28	53	106	327
Stock -ve Days	10	19	30	65	134	393

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of SRPT With Other Asset Classes (Last 1Y)
	SRPT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-87.3%	-0.7%	17.5%	40.7%	2.0%	-4.1%	45.5%
Annualized Volatility	102.3%	17.0%	19.7%	19.9%	16.3%	18.0%	36.9%
Sharpe Ratio	-1.45	-0.21	0.70	1.60	-0.06	-0.38	0.80
Correlation With Other Assets		22.9%	27.0%	5.9%	11.9%	19.9%	16.5%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of SRPT With Other Asset Classes (Last 5Y)
	SRPT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-35.0%	8.1%	16.4%	15.1%	12.9%	6.6%	50.5%
Annualized Volatility	70.1%	14.6%	17.2%	15.6%	18.9%	19.1%	49.2%
Sharpe Ratio	-0.26	0.39	0.78	0.77	0.57	0.26	0.77
Correlation With Other Assets		20.5%	23.0%	4.2%	7.7%	17.0%	8.5%

Based On 10-Year Data

		Comparison of SRPT With Other Asset Classes (Last 10Y)
	SRPT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-4.2%	9.2%	14.5%	12.5%	5.3%	5.1%	80.1%
Annualized Volatility	77.5%	16.7%	18.0%	14.7%	17.7%	20.9%	56.2%
Sharpe Ratio	0.32	0.45	0.69	0.69	0.23	0.22	0.97
Correlation With Other Assets		25.4%	26.0%	1.4%	10.6%	18.5%	8.8%

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	17,686,193
Short Interest: % Change Since 9302025	-9.8%
Average Daily Volume	6,424,974
Days-to-Cover Short Interest	2.75
Basic Shares Quantity	98,005,000
Short % of Basic Shares	18.0%

Returns Analyses

	Title
0	Sarepta Therapeutics Stock Fell 34% in a Day, What Now?
1	Sarepta Therapeutics Stock Return Comparison
2	Sarepta Therapeutics Total Shareholder Return (TSR): 43.9% in 2022 and 0.1% 3-yr returns (below peer average)
3	Sarepta Therapeutics (SRPT) Stock Return: AI Predicts SRPT Average and Excess Return After a Fall or Rise

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8062025	10-Q 6/30/2025
3312025	5062025	10-Q 3/31/2025
12312024	2282025	10-K 12/31/2024
9302024	11062024	10-Q 9/30/2024
6302024	8072024	10-Q 6/30/2024
3312024	5012024	10-Q 3/31/2024
12312023	2282024	10-K 12/31/2023
9302023	11012023	10-Q 9/30/2023
6302023	8022023	10-Q 6/30/2023
3312023	5022023	10-Q 3/31/2023
12312022	2282023	10-K 12/31/2022
9302022	11022022	10-Q 9/30/2022
6302022	8022022	10-Q 6/30/2022
3312022	5042022	10-Q 3/31/2022
12312021	3012022	10-K 12/31/2021
9302021	11032021	10-Q 9/30/2021

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Sarepta Therapeutics (SRPT)

Market Price (11/5/2025): $16.53 | Market Cap: $1.6 BilSector: Health Care | Industry: Biotechnology

Sarepta Therapeutics (SRPT)

Market Price (11/5/2025): $16.53Market Cap: $1.6 BilSector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

SRPT Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Sarepta Therapeutics (SRPT)

Interactive Breakdown

Better Bets than Sarepta Therapeutics (SRPT)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Sarepta Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (11/5/2025): $16.53 | Market Cap: $1.6 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (11/5/2025): $16.53
Market Cap: $1.6 Bil
Sector: Health Care
Industry: Biotechnology